A new humanized antibody, derived from a mouse antibody, has been engineered to target CD99, a protein overexpressed in T-cell acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL). The original mouse antibody was effective at killing leukemia cells but could trigger an immune response in patients. The humanized version is designed to avoid this problem. Studies show that the humanized antibody maintains the ability to bind to CD99 and induce cell death in leukemia cells, while not harming healthy cells. This research offers a promising new avenue for targeted therapy for these aggressive cancers.
Funding
Chiang Mai University and Fundamental Fund 2024.
Original Paper
Title of original paper: Exploring the Biological Activity of a Humanized Anti-CD99 ScFv and Antibody for Targeting T Cell Malignancies.
Journal: Biomolecules
DOI: https://doi.org/10.3390/biom14111422